Your browser doesn't support javascript.
loading
Distribution of serotypes and antibiotic resistance of invasive Pseudomonas aeruginosa in a multi-country collection.
Nasrin, Shamima; Hegerle, Nicolas; Sen, Shaichi; Nkeze, Joseph; Sen, Sunil; Permala-Booth, Jasnehta; Choi, Myeongjin; Sinclair, James; Tapia, Milagritos D; Johnson, J Kristie; Sow, Samba O; Thaden, Joshua T; Fowler, Vance G; Krogfelt, Karen A; Brauner, Annelie; Protonotariou, Efthymia; Christaki, Eirini; Shindo, Yuichiro; Kwa, Andrea L; Shakoor, Sadia; Singh-Moodley, Ashika; Perovic, Olga; Jacobs, Jan; Lunguya, Octavie; Simon, Raphael; Cross, Alan S; Tennant, Sharon M.
Afiliación
  • Nasrin S; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
  • Hegerle N; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Sen S; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
  • Nkeze J; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Sen S; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
  • Permala-Booth J; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Choi M; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
  • Sinclair J; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Tapia MD; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
  • Johnson JK; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Sow SO; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
  • Thaden JT; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Fowler VG; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
  • Krogfelt KA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Brauner A; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
  • Protonotariou E; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Christaki E; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W. Baltimore St. - HSF1 Room 480, Baltimore, MD, 21201, USA.
  • Shindo Y; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Kwa AL; Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Shakoor S; Centre pour le Développement des Vaccins, Mali, Bamako, Mali.
  • Singh-Moodley A; Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA.
  • Perovic O; Division of Infectious Diseases and International Health, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Jacobs J; Duke Clinical Research Institute, Durham, NC, USA.
  • Lunguya O; Statens Serum Institut, Copenhagen, Denmark.
  • Simon R; Department of Natural Sciences and Environment, Roskilde University, Roskilde, Denmark.
  • Cross AS; Department of Microbiology, Tumor and Cell Biology, Division of Clinical Microbiology, Karolinska Institutet and Karolinska University Hospital, 17176, Stockholm, Sweden.
  • Tennant SM; Department of Microbiology, AHEPA University Hospital, Thessaloniki, Greece.
BMC Microbiol ; 22(1): 13, 2022 01 06.
Article en En | MEDLINE | ID: mdl-34991476
ABSTRACT

BACKGROUND:

Pseudomonas aeruginosa is an opportunistic pathogen that causes a wide range of acute and chronic infections and is frequently associated with healthcare-associated infections. Because of its ability to rapidly acquire resistance to antibiotics, P. aeruginosa infections are difficult to treat. Alternative strategies, such as a vaccine, are needed to prevent infections. We collected a total of 413 P. aeruginosa isolates from the blood and cerebrospinal fluid of patients from 10 countries located on 4 continents during 2005-2017 and characterized these isolates to inform vaccine development efforts. We determined the diversity and distribution of O antigen and flagellin types and antibiotic susceptibility of the invasive P. aeruginosa. We used an antibody-based agglutination assay and PCR for O antigen typing and PCR for flagellin typing. We determined antibiotic susceptibility using the Kirby-Bauer disk diffusion method.

RESULTS:

Of the 413 isolates, 314 (95%) were typed by an antibody-based agglutination assay or PCR (n = 99). Among the 20 serotypes of P. aeruginosa, the most common serotypes were O1, O2, O3, O4, O5, O6, O8, O9, O10 and O11; a vaccine that targets these 10 serotypes would confer protection against more than 80% of invasive P. aeruginosa infections. The most common flagellin type among 386 isolates was FlaB (41%). Resistance to aztreonam (56%) was most common, followed by levofloxacin (42%). We also found that 22% of strains were non-susceptible to meropenem and piperacillin-tazobactam. Ninety-nine (27%) of our collected isolates were resistant to multiple antibiotics. Isolates with FlaA2 flagellin were more commonly multidrug resistant (p = 0.04).

CONCLUSIONS:

Vaccines targeting common O antigens and two flagellin antigens, FlaB and FlaA2, would offer an excellent strategy to prevent P. aeruginosa invasive infections.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pseudomonas aeruginosa / Farmacorresistencia Bacteriana Límite: Humans Idioma: En Revista: BMC Microbiol Asunto de la revista: MICROBIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pseudomonas aeruginosa / Farmacorresistencia Bacteriana Límite: Humans Idioma: En Revista: BMC Microbiol Asunto de la revista: MICROBIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos